Project information
Understanding the eIF4F role in melanoma (eIF4F in melanoma)

Project Identification
Project Period
1/2022 - 12/2022
Investor / Pogramme / Project type
Masaryk University
MU Faculty or unit
Faculty of Medicine

Acquired resistance to BRAF and MEK inhibitors leads to ERK pathway reactivation and rapid disease progression in melanoma patients. Enhanced eIF4F activity is a potential therapeutic target as it was linked to the drug resistance. This project will provide new mechanistic insight into the link between eIF4F and ERK signaling in melanoma. Our findings could help to increase melanoma patient survival rates.

You are running an old browser version. We recommend updating your browser to its latest version.

More info